Table 1

Clinical characteristics of the study population according to diabetes subgroup allocation

SAIDSIDDSIRDMODMARDP
N (% of study sample)87 (21)12 (3)39 (9)133 (32)143 (35)
Age, years34.5 (25.9; 46.2)46.3 (33.4; 52.9)56.4 (50.7; 64.8)43.9 (35.3; 53.1)59.8 (53.8; 64.5)<0.0001
Sex (men/women), %59.7/40.391.7/8.364.1/35.957.1/42.971.3/28.70.02
BMI, kg/m2 24.0 (21.9; 26.5)27.1 (24.5; 29.0)34.9 (31.1; 37.4)33.7 (30.0; 38.5)27.3 (25.4; 29.9)<0.0001
Waist circumference, cm86.0 (76.5; 96.0)94.0 (82.2; 106.0)114.0 (106.0; 122.0)109.5 (98.2; 119.0)96.1 (90.0; 104.0)<0.0001
HOMA2-B47.8 (34.9; 69.3)35.8 (24.1; 45.2)165.9 (136.5; 187.6)91.2 (70.4; 119.9)81.6 (63.3; 105.9)<0.0001
HOMA2-IR1.0 (0.7; 1.3)1.4 (1.0; 2.7)4.4 (3.8; 5.5)2.7 (1.9; 3.4)1.8 (1.4; 2.3)<0.0001
Total cholesterol, mg/dL185.0 (163.5; 213.5)196.5 (190.5; 200.0)203.5 (173.5; 228.5)198.5 (167.5; 231.5)197.5 (173.5; 226.5)0.13
Triglycerides, mg/dL74.3 (53.4; 109.0)100.1 (66.1; 191.6)176.6 (110.5; 243.6)141.3 (91.5; 206.0)109.6 (83.0; 152.2)<0.0001
HbA1c, %6.4 (6.0; 7.1)8.8 (8.0; 10.2)6.0 (5.8; 6.3)6.4 (5.8; 7.0)6.1 (5.8; 6.5)<0.0001
HbA1c, mmol/mol46.4 (42.1; 54.1)72.7 (63.4; 87.4)42.1 (39.9; 45.3)46.4 (39.9; 53.0)43.1 (39.9; 47.5)<0.0001
eGFR (mL/min per 1.73 m2)101.0 (86.7; 110.3)102.6 (92.1; 114.8)78.6 (68.7; 88.8)95.4 (85.3; 108.3)87.6 (75.9; 97.7)<0.0001
CKD, %007.93.06.40.05
Known diabetes duration, days162 (123; 255)113.0 (49.5; 192.0)197 (124; 279)179 (122; 176)194 (132; 266)0.52
Hypertension, %25.641.778.961.075.7<0.0001
Antihypertensive medication, %10.316.764.145.151.0<0.0001
Lipid-lowering medication, %2.38.330.79.825.2<0.0001
Glucose-lowering medication (insulin/metformin/none/other), %77/7/11/550/25/8/170/67/25/819/33/38/1010/35/49/6<0.0001
GADA >0.9 units/mL, %1000000<0.0001
ICA >20 JDF units, %83.98.32.66.02.8<0.00001
  • Data are presented as median (25th percentile; 75th percentile) unless otherwise indicated. The frequency of missing data are <2% for each variable. CKD was defined by eGFR <60 mL/min/1.73 m2 (calculated using the CKD-EPI equation based on creatinine and cystatin C). Boldface type indicates significant P values <0.05. CKD, chronic kidney disease; JDF, Juvenile Diabetes Foundation.